Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GenovaTSE:9341 -1.32%78 EV-to-EBIT is 7.25 as of Sep. 12, 2026, which is 30% below its 10-year median of 10.41. GuruFocus rates TSE:9341 with a GF Score™ of 78/100 and a GF Value™ of 円2,056.60 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 475 Medical Devices & Instruments companies, Genova ranks better than 83.16% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Genova's Enterprise Value is 円7,040 Mil.
Genova's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was 円972 Mil. Therefore, Genova's EV-to-EBIT for today is 7.25.
The historical rank and industry rank for Genova's EV-to-EBIT or its related term are showing as below:
TSE:9341'
s EV-to-EBIT Range Over the Past 10 Years
Min: 3.25 Med: 10.41 Max: 83.51
Current: 7.25
During the past 6 years, the highest EV-to-EBIT of Genova was 83.51. The lowest was 3.25. And the median was 10.41.
TSE:9341's EV-to-EBIT is ranked better than 83.16% of 475
companies
in the Medical Devices & Instruments industry
Industry Median: 18.21
vs TSE:9341: 7.25
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Genova's Enterprise Value for the quarter that ended in Mar. 2026 was 円4,954 Mil.
Genova's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円972 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genova EV-to-EBIT Related Terms
Genova EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Genova's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Genova's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genova EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Genova's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Genova's EV-to-EBIT falls into.
Genova's current Enterprise Value is 円7,040 Mil.
Genova's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円972 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genova (TSE:9341) has a EV-to-EBIT of 7.25 as of Sep. 12, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Genova and its competitors. This is 30% below median its historical median of 10.41. Over the past decade, Genova's EV-to-EBIT has ranged from 3.25 to 83.51. According to the industry distribution chart, Genova ranks #80 out of 475 companies in the Medical Devices & Instruments industry, placing it in the top 16.8%.
Is Genova's EV-to-EBIT too high?
Genova's current EV-to-EBIT of 7.25 is 30% below median its 10-year median of 10.41. Over the past 10 years, this metric has ranged from a low of 3.25 to a high of 83.51. The Medical Devices & Instruments industry median EV-to-EBIT is 18.21. Genova's value of 7.25 is 60.2% below this industry median. Based on the distribution chart, Genova ranks #80 out of 475 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Genova has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Genova's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Genova ranks #80 out of 475 companies for EV-to-EBIT. This places Genova in the top 17% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 18.21. Genova's value of 7.25 is 60.2% below this benchmark. Historically, Genova's own EV-to-EBIT has ranged from 3.25 to 83.51 over the past decade. While the company's 10-year median is 10.41 vs. the industry median of 18.21, Genova has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.21, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genova's current EV-to-EBIT of 7.25 is 60.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Genova and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genova's current EV-to-EBIT is 7.25, which is 30% below median its own 10-year median of 10.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genova stock overvalued right now?
Based on GuruFocus' analysis, Genova (TSE:9341) is currently considered Possible Value Trap. The stock's GF Value™ is 円2,056.60, compared to a current price of 円597.00 — trading 71% below its estimated fair value. The current EV-to-EBIT is 7.25, which is 30% below median its 10-year median of 10.41 and 60.2% below the Medical Devices & Instruments industry median of 18.21. Genova's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Genova (TSE:9341), the current EV-to-EBIT is 7.25 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genova (TSE:9341) Overvalued in 2026?
Based on GuruFocus' analysis, Genova stock appears to be undervalued.
The current stock price of 円597.00 is trading 71% below its estimated GF Value™ of 円2,056.60.
GuruFocus considers Genova to be Possible Value Trap.
Key valuation signals for TSE:9341:
EV-to-EBIT: 7.25 (30% below median its 10-year median of 10.41)
GF Value™: 円2,056.60 vs. price of 円597.00 (71% below fair value)
Industry Position: 60.2% below the Medical Devices & Instruments median (#80 of 475)
No single metric tells the full story. See the TSE:9341 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genova Inc manages operations of the medical information site and sales of automatic reception and payment machines for clinics. The group operates in two reportable segments: Medical Platform Business and the Smart Clinic Project. The majority of its revenue is generated from the Medical Platform Business, which operates an online media site (Medical Dock) that provides preventive information and health knowledge to users (patients) on diseases and symptoms. In addition, it also supports users in finding a family doctor that suits them. The Smart Clinic Business develops and provides services that improve the convenience and efficiency of non-medical procedures at medical institutions.
78GF Score
Get the complete analysis for TSE:9341
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:9341 has been successfully added to your 
